Pharmaceutical

Bristol Myers Squibb acquires Karuna Therapeutics for $14bn

Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.

Mar 20, 2024 - 00:00
Bristol Myers Squibb acquires Karuna Therapeutics for $14bn
Bristol Myers Squibb (BMS) has concluded the acquisition of Karuna Therapeutics for an equity value totalling $14bn.
Read the original article

Tags:

Previous Article

Microsoft and NVIDIA expand collaboration in healthcare innovation

Next Article

No Proof of Brain Injury in ‘Havana Syndrome’ Patients

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Takeda wins EU approval for paediatric use of Takhzyro in HAE

Takeda wins EU approval for paediatric use of Takhzyro ...

Nov 20, 2023

GITEX GLOBAL 2024: Huawei launches a series of industrial digital and intelligent transformation solutions, and flagship products

GITEX GLOBAL 2024: Huawei launches a series of industri...

Oct 16, 2024

STAT+: Philips pays $2.4 million for allegedly giving kickbacks to sleep labs

STAT+: Philips pays $2.4 million for allegedly giving k...

Dec 27, 2023